Artiva Biotherapeutics CEO Fred Aslan disposes of 23,429 common shares worth $255,725
ARTV•CEO share sale reported in SEC filing
- Artiva Biotherapeutics CEO Fred Aslan sold 23,429 shares of common stock on Sept. 8, 2026.
- Weighted average sale price: $10.92 per share.
- Directly held stake fell to 1,449,765 shares following the sale.
